ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Successful Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors.

C. Ensor, R. Winstead, B. Johnson, M. Morrell, S. Kilaru, C. Moore, J. Hayanga, A. Zeevi, E. Lendermon, J. McDyer.

University of Pittsburgh, Pittsburgh, PA.

Meeting: 2016 American Transplant Congress

Abstract number: 152

Keywords: Co-stimulation

Session Information

Session Name: Concurrent Session: Lung Transplant: Moving the Field Forward

Session Type: Concurrent Session

Date: Sunday, June 12, 2016

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:42pm-5:54pm

Location: Room 313

Purpose: Describe response of belatacept (BELA) immunosuppression regimen (ISR) conversion in lung transplantation recipients (LTRs) after calcineurin inhibitor (CNI) failure on incidence of cellular rejection (ACR), bronchiolitis obliterans syndrome (BOS) progression, infections, and cardiorenal function.

Methods: Single center, retrospective medical record review of adult LTRs before and after conversion to BELA from CNI-based ISRs. Patients were evaluated at fixed time points before and after BELA conversion. Primary outcome was incidence of ACR (composite rejection standardized score (CRSS)). Secondary outcomes included incidence of infections (positive bronchoalveolar lavage or blood cultures), change in FEV1, BOS progression, death; change in MAP and serum creatinine (SCr). Descriptive statistics; both univariate parametric and nonparametric statistical tests were used to assess characteristics and outcomes.

Results: 8 LTRs underwent BELA conversion and had mean of 287 (range 62-1064) days of follow-up. 5 (62.5%) were male, mean age at transplant was 53.8 (SD 9.4) years, 7 (87.5%) received bilateral lungs primarily for COPD (4, 50%) or ILD (2, 25%), 8 (100%) were EBV D+R+, 6 (75%) received alemtuzumab induction, 4 (50%) were converted for TTP; 3 (37.5%) for PRES; 1 (12.5%) for BOS. 6 (75%) received labeled dose (10 mg/kg then 5 mg/kg); 2 (25%) received conversion dose (5 mg/kg). ACR was not different before and after BELA conversion (CRSS, 0.55 vs. 0.35, p=0.49). Incidences of infections were not different: BAL gram negative (0.79 vs. 0.57, p=0.44), BAL gram positive (0.17 vs. 0, p=0.32), viral (0.04 vs. 0.13, p=0.18), and fungal (0.35 vs. 0.4, p=0.19). FEV1 prior to BELA conversion and lowest FEV1 after BELA conversion were not different (1.51 vs. 1.44, p=0.38). 1 (12.5%) patient experienced BOS progression. 3 patients died a mean of 445 days after BELA conversion. MAP (95.1 vs. 92.4 mmHg, p=0.81) and SCr (2.63 vs. 1.8 mg/dL, p=0.24) were not different 3 months prior to and 3 months after BELA conversion.

Conclusion: BELA-based ISRs appear to produce reasonable results in LTRs intolerant to CNI-based ISRs in this small case series. SCr was numerically lower after BELA conversion. Larger prospective trials clearly appear warranted.

CITATION INFORMATION: Ensor C, Winstead R, Johnson B, Morrell M, Kilaru S, Moore C, Hayanga J, Zeevi A, Lendermon E, McDyer J. Successful Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Ensor C, Winstead R, Johnson B, Morrell M, Kilaru S, Moore C, Hayanga J, Zeevi A, Lendermon E, McDyer J. Successful Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/successful-maintenance-belatacept-based-immunosuppression-in-lung-transplantation-recipients-who-failed-calcineurin-inhibitors/. Accessed June 2, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences